What is Fluoxetine/Olanzapine?
Fluoxetine is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs).
Olanzapine is an antipsychotic medication. These drugs affect chemicals in the brain.
Fluoxetine/Olanzapine is a combination medicine used to treat depression caused by bipolar disorder (manic depression). Fluoxetine/Olanzapine is also used to treat depression after at least 2 other medications have been tried without successful treatment of symptoms.
Fluoxetine/Olanzapine may also be used for other purposes not listed in this medication guide.
Fluoxetine/Olanzapine indications
Depressive Episodes Associated with Bipolar I Disorder
Fluoxetine/Olanzapine® is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder.
Treatment Resistant Depression
Fluoxetine/Olanzapine is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adults who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode).
How should I use Fluoxetine/Olanzapine?
Use Fluoxetine/Olanzapine as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Fluoxetine/Olanzapine comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Fluoxetine/Olanzapine refilled.
- Take Fluoxetine/Olanzapine by mouth on an empty stomach or with food.
- Take Fluoxetine/Olanzapine in the evening, unless your doctor tells you otherwise.
- Continue to take Fluoxetine/Olanzapine even if you feel well. Do not miss any doses.
- Do not suddenly stop taking Fluoxetine/Olanzapine without checking with your doctor. Side effects may occur. They may include mental or mood changes, agitation, anxiety, irritability, numbness or tingling of the skin, dizziness, confusion, headache, trouble sleeping, or unusual tiredness. You will be closely monitored when you start Fluoxetine/Olanzapine and whenever a change in dose is made.
- If you miss a dose of Fluoxetine/Olanzapine, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Fluoxetine/Olanzapine.
Uses of Fluoxetine/Olanzapine in details
Use: Labeled Indications
Depression, acute (associated with bipolar I disorder): Treatment of acute depressive episodes associated with bipolar I disorder
Depression, treatment-resistant: Treatment of treatment-resistant depression (eg, unresponsive to 2 trials of different antidepressants in the current episode)
Fluoxetine/Olanzapine dosage
Fluoxetine/Olanzapine Dosage
Generic name: Olanzapine 6mg, Fluoxetine hydrochloride 25mg
Dosage form: capsule
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Depressive Episodes Associated with Bipolar I Disorder
Adults — Administer Fluoxetine/Olanzapine once daily in the evening, generally beginning with the 6 mg/25 mg (mg olanzapine/mg equivalent fluoxetine) capsule. While food has no appreciable effect on the absorption of olanzapine and fluoxetine given individually, the effect of food on the absorption of Fluoxetine/Olanzapine has not been studied. Make dosage adjustments, if indicated, according to efficacy and tolerability. Antidepressant efficacy was demonstrated with Fluoxetine/Olanzapine in a dose range of olanzapine 6 mg to 12 mg and fluoxetine 25 mg to 50 mg. The safety of doses above 18 mg of olanzapine and 75 mg of fluoxetine has not been evaluated in adult clinical studies. Periodically reexamine the need for continued pharmacotherapy.
Children and Adolescents (10 to 17 years of age) — Administer Fluoxetine/Olanzapine once daily in the evening, generally beginning with the 3 mg/25 mg capsule, without regard to meals, with a recommended target dose within the approved dosing range (6/25; 6/50; 12/25; 12/50 mg). The safety of doses above 12 mg of olanzapine and 50 mg of fluoxetine has not been evaluated in pediatric clinical studies. Periodically reexamine the need for continued pharmacotherapy.
Treatment Resistant Depression
Administer Fluoxetine/Olanzapine once daily in the evening, generally beginning with the 6 mg/25 mg capsule. While food has no appreciable effect on the absorption of olanzapine and fluoxetine given individually, the effect of food on the absorption of Fluoxetine/Olanzapine has not been studied. Adjust dosage, if indicated, according to efficacy and tolerability. Antidepressant efficacy was demonstrated with Fluoxetine/Olanzapine in a dose range of olanzapine 6 mg to 18 mg and fluoxetine 25 mg to 50 mg. The safety of doses above 18 mg/75 mg has not been evaluated in clinical studies. Periodically reexamine the need for continued pharmacotherapy.
Specific Populations
Start Fluoxetine/Olanzapine at 3 mg/25 mg or 6 mg/25 mg in patients with a predisposition to hypotensive reactions, patients with hepatic impairment, or patients who exhibit a combination of factors that may slow the metabolism of Fluoxetine/Olanzapine (female gender, geriatric age, nonsmoking status) or those patients who may be pharmacodynamically sensitive to olanzapine. Titrate slowly and adjust dosage as needed in patients who exhibit a combination of factors that may slow metabolism. Fluoxetine/Olanzapine has not been systematically studied in patients >65 years of age or in patients <10 years of age.
Treatment of Pregnant Women — When treating pregnant women with fluoxetine, a component of Fluoxetine/Olanzapine, the physician should carefully consider the potential risks and potential benefits of treatment. Neonates exposed to SSRIs or SNRIs late in the third trimester have developed complications requiring prolonged hospitalizations, respiratory support, and tube feeding..
Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders
At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Fluoxetine/Olanzapine. Conversely, at least 5 weeks should be allowed after stopping Fluoxetine/Olanzapine before starting an MAOI intended to treat psychiatric disorders.
Use of Fluoxetine/Olanzapine with Other MAOIs such as Linezolid or Methylene Blue
Do not start Fluoxetine/Olanzapine in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered.
In some cases, a patient already receiving Fluoxetine/Olanzapine therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue are judged to outweigh the risks of serotonin syndrome in a particular patient, Fluoxetine/Olanzapine should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for five weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with Fluoxetine/Olanzapine may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue.
The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with Fluoxetine/Olanzapine is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use.
Discontinuation of Treatment with Fluoxetine/Olanzapine
Symptoms associated with discontinuation of fluoxetine, a component of Fluoxetine/Olanzapine, SNRIs, and SSRIs, have been reported.
More about Fluoxetine/Olanzapine (fluoxetine / olanzapine)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 46 Reviews - Add your own review/rating
- Generic Availability
Consumer resources
- Fluoxetine/Olanzapine
- Fluoxetine/Olanzapine (Advanced Reading)
Professional resources
- Fluoxetine/Olanzapine (FDA)
Related treatment guides
- Depression
- Major Depressive Disorder
- Bipolar Disorder
Fluoxetine/Olanzapine interactions
See also:
What other drugs will affect Fluoxetine/Olanzapine?
The risks of using Fluoxetine/Olanzapine in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of Fluoxetine/Olanzapine are applicable to Fluoxetine/Olanzapine. As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug inhibition or enhancement, etc.) is a possibility. In evaluating individual cases, consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration schedules, and monitoring of clinical status.
Monoamine Oxidase Inhibitors (MAOIs)
.
CNS Acting Drugs
Caution is advised if the concomitant administration of Fluoxetine/Olanzapine and other CNS-active drugs is required. In evaluating individual cases, consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration schedules, and monitoring of clinical status.
Serotonergic Drugs
.
Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, Warfarin)
Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs are coadministered with warfarin. Warfarin (20 mg single dose) did not affect olanzapine pharmacokinetics. Single doses of olanzapine did not affect the pharmacokinetics of warfarin. Patients receiving warfarin therapy should be carefully monitored when Fluoxetine/Olanzapine is initiated or discontinued.
Electroconvulsive Therapy (ECT)
There are no clinical studies establishing the benefit of the combined use of ECT and fluoxetine. There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment.
Potential for Other Drugs to Affect Fluoxetine/Olanzapine
Benzodiazepines — Co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine.
Inducers of 1A2 — Carbamazepine therapy (200 mg BID) causes an approximate 50% increase in the clearance of olanzapine. This increase is likely due to the fact that carbamazepine is a potent inducer of CYP1A2 activity. Higher daily doses of carbamazepine may cause an even greater increase in olanzapine clearance.
Alcohol — Ethanol (45 mg/70 kg single dose) did not have an effect on olanzapine pharmacokinetics.
Inhibitors of CYP1A2 — Fluvoxamine decreases the clearance of olanzapine. This results in a mean increase in olanzapine Cmax following fluvoxamine administration of 54% in female nonsmokers and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%, respectively. Lower doses of the olanzapine component of Fluoxetine/Olanzapine should be considered in patients receiving concomitant treatment with fluvoxamine.
The Effect of Other Drugs on Olanzapine — Fluoxetine, an inhibitor of CYP2D6, decreases olanzapine clearance a small amount. Agents that induce CYP1A2 or glucuronyl transferase enzymes, such as omeprazole and rifampin, may cause an increase in olanzapine clearance. The effect of CYP1A2 inhibitors, such as fluvoxamine and some fluoroquinolone antibiotics, on Fluoxetine/Olanzapine has not been evaluated. Although olanzapine is metabolized by multiple enzyme systems, induction or inhibition of a single enzyme may appreciably alter olanzapine clearance. Therefore, a dosage increase (for induction) or a dosage decrease (for inhibition) may need to be considered with specific drugs.
Potential for Fluoxetine/Olanzapine to Affect Other Drugs
Pimozide — Concomitant use of Fluoxetine/Olanzapine and pimozide is contraindicated. Pimozide can prolong the QT interval. Fluoxetine/Olanzapine can increase the level of pimozide through inhibition of CYP2D6. Fluoxetine/Olanzapine can also prolong the QT interval. Clinical studies of pimozide with other antidepressants demonstrate an increase in drug interaction or QTc prolongation. While a specific study with pimozide and Fluoxetine/Olanzapine has not been conducted, the potential for drug interactions or QTc prolongation warrants restricting the concurrent use of pimozide and Fluoxetine/Olanzapine.
Carbamazepine — Patients on stable doses of carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment.
Alcohol — The coadministration of ethanol with Fluoxetine/Olanzapine may potentiate sedation and orthostatic hypotension.
Thioridazine — Thioridazine should not be administered with Fluoxetine/Olanzapine or administered within a minimum of 5 weeks after discontinuation of Fluoxetine/Olanzapine, because of the risk of QT prolongation.
In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared with the rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of CYP2D6 isozyme activity. Thus, this study suggests that drugs that inhibit CYP2D6, such as certain SSRIs, including fluoxetine, will produce elevated plasma levels of thioridazine.
Thioridazine administration produces a dose-related prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsades de pointes-type arrhythmias and sudden death. This risk is expected to increase with fluoxetine-induced inhibition of thioridazine metabolism.
Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated thioridazine plasma levels, thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued.
Tricyclic Antidepressants (TCAs) — Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.
In 2 fluoxetine studies, previously stable plasma levels of imipramine and desipramine have increased > 2- to 10fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCA may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when Fluoxetine/Olanzapine is coadministered or has been recently discontinued.
Antihypertensive Agents — Because of the potential for olanzapine to induce hypotension, Fluoxetine/Olanzapine may enhance the effects of certain antihypertensive agents.
Levodopa and Dopamine Agonists — The olanzapine component of Fluoxetine/Olanzapine may antagonize the effects of levodopa and dopamine agonists.
Benzodiazepines — Multiple doses of olanzapine did not influence the pharmacokinetics of diazepam and its active metabolite N-desmethyldiazepam.
When concurrently administered with fluoxetine, the half-life of diazepam may be prolonged in some patients. Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels.
Clozapine — Elevation of blood levels of clozapine has been observed in patients receiving concomitant fluoxetine.
Haloperidol — Elevation of blood levels of haloperidol has been observed in patients receiving concomitant fluoxetine.
Phenytoin — Patients on stable doses of phenytoin have developed elevated plasma levels of phenytoin with clinical phenytoin toxicity following initiation of concomitant fluoxetine.
Drugs Metabolized by CYP2D6 — In vitro studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP2D6. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by this enzyme.
Fluoxetine inhibits the activity of CYP2D6 and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for a decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (including but not limited to, flecainide, propafenone, vinblastine, and TCAs).
Drugs Metabolized by CYP3A — In vitro studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP3A. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes.
In an in vivo interaction study involving the coadministration of fluoxetine with single doses of terfenadine (a CYP3A substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam. These data indicate that fluoxetine's extent of inhibition of CYP3A activity is not likely to be of clinical significance.
Effect of Olanzapine on Drugs Metabolized by Other CYP Enzymes — In vitro studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP1A2, CYP2C9, and CYP2C19. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes.
Lithium — Multiple doses of olanzapine did not influence the pharmacokinetics of lithium.
There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine. Cases of lithium toxicity and increased serotonergic effects have been reported. Lithium levels should be monitored in patients taking Fluoxetine/Olanzapine concomitantly with lithium.
Drugs Tightly Bound to Plasma Proteins — The in vitro binding of Fluoxetine/Olanzapine to human plasma proteins is similar to the individual components. The interaction between Fluoxetine/Olanzapine and other highly protein-bound drugs has not been fully evaluated. Because fluoxetine is tightly bound to plasma protein, the administration of fluoxetine to a patient taking another drug that is tightly bound to protein (e.g., Coumadin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect. Conversely, adverse effects may result from displacement of protein-bound fluoxetine by other tightly bound drugs.
Valproate — In vitro studies using human liver microsomes determined that olanzapine has little potential to inhibit the major metabolic pathway, glucuronidation, of valproate. Further, valproate has little effect on the metabolism of olanzapine in vitro. Thus, a clinically significant pharmacokinetic interaction between olanzapine and valproate is unlikely.
Biperiden — Multiple doses of olanzapine did not influence the pharmacokinetics of biperiden.
Theophylline — Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites.
Drugs that Prolong the QT Interval
Do not use Fluoxetine/Olanzapine in combination with thioridazine or pimozide. Use Fluoxetine/Olanzapine with caution in combination with other drugs that cause QT prolongation. These include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). Fluoxetine is primarily metabolized by CYP2D6. Concomitant treatment with CYP2D6 inhibitors can increase the concentration of fluoxetine. Concomitant use of other highly protein-bound drugs can increase the concentration of fluoxetine.
Drug Abuse And Dependence
Dependence
Fluoxetine/Olanzapine, as with Fluoxetine/Olanzapine, has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. While the clinical studies did not reveal any tendency for any drug-seeking behavior, these observations were not systematic, and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of Fluoxetine/Olanzapine (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).
In studies in rats and rhesus monkeys designed to assess abuse and dependence potential, olanzapine alone was shown to have acute depressive CNS effects but little or no potential of abuse or physical dependence at oral doses up to 15 (rat) and 8 (monkey) times the MRHD (20 mg) on a mg/m² basis.
Fluoxetine/Olanzapine side effects
See also:
What are the possible side effects of Fluoxetine/Olanzapine?
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.
Clinical Trials Experience
Adverse reactions were recorded by clinical investigators using descriptive terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a limited (i.e., reduced) number of standardized reaction categories.
In the tables and tabulations that follow, MedDRA or COSTART Dictionary terminology has been used to classify reported adverse reactions. The data in the tables represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is possible that reactions reported during therapy were not necessarily related to drug exposure.
The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing clinician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.
Adults
The information below is derived from a clinical study database for Fluoxetine/Olanzapine consisting of 2547 patients with treatment resistant depression, depressive episodes associated with Bipolar I Disorder, Major Depressive Disorder with psychosis, or sexual dysfunction with approximately 1085 patient-years of exposure. The conditions and duration of treatment with Fluoxetine/Olanzapine varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, fixed-dose and dose-titration studies, and short-term or long-term exposure.
Adverse Reactions Associated with Discontinuation of Treatment in Short-Term, Controlled Studies Including Depressive Episodes Associated with Bipolar I Disorder and Treatment Resistant Depression
Overall, 11.3% of the 771 patients in the Fluoxetine/Olanzapine group discontinued due to adverse reactions compared with 4.4% of the 477 patients for placebo. Adverse reactions leading to discontinuation associated with the use of Fluoxetine/Olanzapine (incidence of at least 1% for Fluoxetine/Olanzapine and greater than that for placebo) using MedDRA Dictionary coding were weight increased (2%) and sedation (1%) versus placebo patients which had 0% incidence of weight increased and sedation.
Commonly Observed Adverse Reactions in Short-Term, Controlled Studies Including Depressive Episodes Associated with Bipolar I Disorder and Treatment Resistant Depression
The most commonly observed adverse reactions associated with the use of Fluoxetine/Olanzapine (incidence ≥ 5% and at least twice that for placebo in the Fluoxetine/Olanzapine-controlled database) using MedDRA Dictionary coding were: disturbance in attention, dry mouth, fatigue, hypersomnia, increased appetite, peripheral edema, sedation, somnolence, tremor, vision blurred, and weight increased. Adverse reactions reported in clinical trials of olanzapine and fluoxetine in combination are generally consistent with treatment-emergent adverse reactions during olanzapine or fluoxetine monotherapy.
Adverse Reactions Occurring at an Incidence of 2% or More in Short-Term Controlled Studies Including Depressive Episodes Associated with Bipolar I Disorder and Treatment Resistant Depression
Table 13 enumerates the treatment-emergent adverse reactions associated with the use of Fluoxetine/Olanzapine (incidence of at least 2% for Fluoxetine/Olanzapine and twice or more than for placebo). The Fluoxetine/Olanzapine-controlled column includes patients with various diagnoses while the placebo column includes only patients with bipolar depression and major depression with psychotic features.
Table 13: Treatment-Emergent Adverse Reactions: Incidence in the Adult Controlled Clinical Studies
| System Organ Class | Adverse Reaction | Percentage of Patients Reporting Event | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fluoxetine/Olanzapine-Controlled (N=771) | Placebo (N=477) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Eye disorders | Vision blurred | 5 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Gastrointestinal disorders | Dry mouth | 15 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Flatulence | 3 | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abdominal distension | 2 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| General disorders and administration site conditions | Fatigue | 12 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EdemaThese terms represent serious adverse events but do not meet the definition for adverse drug reactions. They are included here because of their seriousness.
Fluoxetine/Olanzapine contraindicationsSee also: Monoamine Oxidase Inhibitors (MAOIs)The use of MAOIs intended to treat psychiatric disorders with Fluoxetine/Olanzapine or within 5 weeks of stopping treatment with Fluoxetine/Olanzapine is contraindicated because of an increased risk of serotonin syndrome. The use of Fluoxetine/Olanzapine within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated. Starting Fluoxetine/Olanzapine in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome..
Other Contraindications
Pimozide and thioridazine prolong the QT interval. Fluoxetine/Olanzapine can increase the levels of pimozide and thioridazine through inhibition of CYP2D6. Fluoxetine/Olanzapine can also prolong the QT interval. Active ingredient matches for Fluoxetine/Olanzapine:Fluoxetine/Olanzapine
References
ReviewsThe results of a survey conducted on ndrugs.com for Fluoxetine/Olanzapine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Fluoxetine/Olanzapine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reportsConsumer reported usefulNo survey data has been collected yetConsumer reported price estimatesNo survey data has been collected yetConsumer reported time for resultsNo survey data has been collected yetConsumer reported ageNo survey data has been collected yetConsumer reviews
Information checked by Dr. Sachin Kumar, MD Pharmacology More about Fluoxetine/OlanzapineClinician Information
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
